Cash flows from operating activities: | |
Net income | 1.57B |
Adjustments to reconcile net income to net cash provided by operating activities: | |
Depreciation of long-term assets | 89.6M |
Amortization | |
Allocation of pre-paid royalties | |
Provision (benefit) for accounts receivable allowances | |
Deferred income taxes | -256.8M |
Impairment of acquired in-process research and development | 187.1M |
Change in value of contingent consideration | |
Share-based compensation expense | 451.7M |
Equity in (gains) losses of affiliated companies | |
Share-based employee benefit plan expense | 28.7M |
Unrealized change in value of foreign currency forward contracts | |
Realized (gain) loss on marketable securities available for sale | |
Other, net | -9.3M |
Change in current assets and liabilities, excluding the effect of acquisitions: | |
Accounts receivable | -143.8M |
Inventory | -62.3M |
Other operating assets | 137.2M |
Assets held for sale, net | |
Accounts payable and other operating liabilities | 163.9M |
Income tax payable | 27.9M |
Deferred revenue | 11.6M |
Net cash provided by operating activities | 2.63B |
Cash flows from investing activities: | |
Proceeds from sales of marketable securities available for sale | |
Purchases of marketable securities available for sale | |
Payments for acquisition of business, net of cash acquired | 0 |
Proceeds from the sale of non-core assets, net | |
Capital expenditures | -169.8M |
Investment in affiliated companies | |
Purchases of investment securities | |
Net cash provided by (used in) investing activities | -298M |
Cash flows from financing activities: | |
Payment for treasury shares | -2.03B |
Net proceeds from exercise of common stock options and warrants | 190.8M |
Excess tax benefit from share-based compensation arrangements | 129.8M |
Net cash provided by (used in) financing activities | -1.7B |
Effect of currency rate changes on cash and cash equivalents | |
Net increase (decrease) in cash and cash equivalents | 642.3M |
Cash and cash equivalents at beginning of period | 4.88B |
Cash and cash equivalents at end of period | 5.52B |
Supplemental schedule of non-cash investing and financing activity: | |
Contingent consideration issued in acquisition of Gloucester | |
Change in net unrealized (gain) loss on marketable securities available for sale | 361M |
Matured shares tendered in connection with stock option exercises | |
Supplemental disclosure of cash flow information: | |
Interest paid | 463.3M |
Income taxes paid | 345.1M |